Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Jan 2018
Randomized Controlled Trial Multicenter Study Comparative StudyAdalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
Previous clinical trials have not evaluated improvement in nail psoriasis as a primary end point. ⋯ After 26 weeks of adalimumab treatment, significant improvements were seen in the primary and all ranked secondary end points and in signs and symptoms of moderate-to-severe nail psoriasis versus with placebo and no new safety risks were identified.